❯ Isomorphic Labs raises $5 billion in Series C to advance AI-designed drug candidates and clinical development
Back in the market after six monthsIsomorphic Labs announced the $5 billion round on November 17. Greenoaks and Sequoia Capital co-led, a16z and other new investors joined, and Alphabet continued investing alongside existing investors including Thrive Capital, GV, CapitalG and Temasek. Thrive led the $2.1 billion Series B in May.
One design engine for two pipelinesIsomorphic uses its proprietary IsoDDE drug design engine to support candidate discovery in both in-house and partnered programs. It has disclosed relationships with Lilly, Novartis and Johnson & Johnson. Partners can bring parts of their research work onto the platform, while the internal programs require Isomorphic to fund its own candidate selection and development.
Moving candidates toward trialsThe new money will support improvements to the underlying simulation and design models, progression of internal and partnered candidates, and infrastructure for research and clinical development. Reuters said the company is working to move its first candidates into clinical trials. Entering the clinic remains the next milestone.
▮ SIGNALThe round funds model development, the in-house pipeline and clinical work in parallel, and the first candidates will show how far the platform can carry a real drug program.